These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38357917)

  • 1. An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin.
    Sneed SL; Reese BB; Laureano AF; Ratnapriya S; Fraschilla I; Jeffrey KL; Coffey GP; Conley PB; Anthony RM
    J Clin Invest; 2024 Feb; 134(4):. PubMed ID: 38357917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.
    Blundell PA; Le NPL; Allen J; Watanabe Y; Pleass RJ
    J Biol Chem; 2017 Aug; 292(31):12994-13007. PubMed ID: 28620050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain.
    Yu X; Vasiljevic S; Mitchell DA; Crispin M; Scanlan CN
    J Mol Biol; 2013 Apr; 425(8):1253-8. PubMed ID: 23416198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.
    Fiebiger BM; Maamary J; Pincetic A; Ravetch JV
    Proc Natl Acad Sci U S A; 2015 May; 112(18):E2385-94. PubMed ID: 25870292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a receptor required for the anti-inflammatory activity of IVIG.
    Anthony RM; Wermeling F; Karlsson MC; Ravetch JV
    Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19571-8. PubMed ID: 19036920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.
    Anthony RM; Nimmerjahn F; Ashline DJ; Reinhold VN; Paulson JC; Ravetch JV
    Science; 2008 Apr; 320(5874):373-6. PubMed ID: 18420934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins.
    Ahmed AA; Giddens J; Pincetic A; Lomino JV; Ravetch JV; Wang LX; Bjorkman PJ
    J Mol Biol; 2014 Sep; 426(18):3166-3179. PubMed ID: 25036289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines.
    Mimura Y; Kelly RM; Unwin L; Albrecht S; Jefferis R; Goodall M; Mizukami Y; Mimura-Kimura Y; Matsumoto T; Ueoka H; Rudd PM
    J Immunol Methods; 2016 Jan; 428():30-6. PubMed ID: 26627984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.
    Mi W; Wanjie S; Lo ST; Gan Z; Pickl-Herk B; Ober RJ; Ward ES
    J Immunol; 2008 Dec; 181(11):7550-61. PubMed ID: 19017944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy.
    Wong AH; Fukami Y; Sudo M; Kokubun N; Hamada S; Yuki N
    J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):275-9. PubMed ID: 25814494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
    Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
    J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):111. PubMed ID: 25546783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.
    Anthony RM; Ravetch JV
    J Clin Immunol; 2010 May; 30 Suppl 1():S9-14. PubMed ID: 20480216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer.
    Lewis BJB; Ville J; Blacquiere M; Cen S; Spirig R; Zuercher AW; Käsermann F; Branch DR
    BMC Immunol; 2019 Dec; 20(1):44. PubMed ID: 31801459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
    Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
    Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin.
    Othy S; Topçu S; Saha C; Kothapalli P; Lacroix-Desmazes S; Käsermann F; Miescher S; Bayry J; Kaveri SV
    Eur J Immunol; 2014 Jul; 44(7):2059-63. PubMed ID: 24700174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Dual Targeting of FcRn and FcγRs
    Monnet C; Jacque E; de Romeuf C; Fontayne A; Abache T; Fournier N; Dupont G; Derache D; Engrand A; Bauduin A; Terrier A; Seifert A; Beghin C; Longue A; Masiello N; Danino L; Nogre M; Raia A; Dhainaut F; Fauconnier L; Togbe D; Reitinger C; Nimmerjahn F; Stevens W; Chtourou S; Mondon P
    Front Immunol; 2021; 12():728322. PubMed ID: 34512662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IVIG in autoimmune disease - Potential next generation biologics.
    Zuercher AW; Spirig R; Baz Morelli A; Käsermann F
    Autoimmun Rev; 2016 Aug; 15(8):781-5. PubMed ID: 27019051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of recombinant human IgG1 Fc with beneficial N-glycosylation pattern for anti-inflammatory activity using genome-edited chickens.
    Park JS; Choi HJ; Jung KM; Lee KY; Shim JH; Park KJ; Kim YM; Han JY
    Commun Biol; 2023 Jun; 6(1):589. PubMed ID: 37264071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.